MedTrace Logo

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969136 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2016-05-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

Conditions

Interventions

DRUG

Drug: EVP-6124

DRUG

Placebo

Sponsors & Collaborators

  • FORUM Pharmaceuticals Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Czechia
  • France
  • Germany
  • Italy
  • Mexico
  • Netherlands
  • South Africa
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969136 on ClinicalTrials.gov